8-K: Bioventus Finalizes Sale of Advanced Rehabilitation Business to Accelmed Partners for $25 Million

Bioventus has completed the sale of its Advanced Rehabilitation business to Accelmed Partners for $25 million in cash, with potential earn-out payments of up to $20 million.

Summary

• Bioventus Inc. has successfully completed the divestiture of its Advanced Rehabilitation business to Accelmed Partners on December 31, 2024.
• The transaction involved the sale of Bioness Neuromodulation Ltd. and assets related to the Rehab Products business.
• Bioventus received a cash payment of $25 million at closing, subject to post-closing adjustments for working capital.
• The company is also eligible for up to $20 million in earn-out payments based on the buyer's revenue and EBITDA performance in 2025 and 2026.
• The divestiture allows Bioventus to focus on its core businesses and improve its financial position.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the successful completion of the divestiture and the cash proceeds received, but tempered by the potential risks and uncertainties associated with the earn-out payments and the company's future performance.

Positives

• The divestiture provides Bioventus with $25 million in immediate cash proceeds.
• The potential for an additional $20 million in earn-out payments could further improve the company's financial position.
• The sale allows Bioventus to streamline its operations and focus on its core business segments.
• The transaction is expected to enhance the company's liquidity.

Risks

• The earn-out payments are contingent on the buyer achieving certain revenue and EBITDA targets, which may not be met.
• The company's future performance is subject to various risks, including competition, regulatory changes, and market acceptance of its products.
• The company is subject to securities litigation and may be subject to similar or other litigation in the future.

Future Outlook

The company expects to use the proceeds from the divestiture to enhance liquidity and focus on its core businesses. The company's future growth, operating margins, market leadership and strategy are subject to various risks and uncertainties.

Management Comments

• The transaction enables Bioventus to continue improving its focus and execution within the Company's core businesses.
• The divestiture will deliver approximately $20 million of net closing proceeds to enhance liquidity.

Industry Context

This divestiture reflects a trend in the medical device industry where companies are streamlining their portfolios to focus on core competencies and improve financial performance. Private equity firms like Accelmed are actively acquiring commercial-stage HealthTech companies.

Comparison to Industry Standards

• The divestiture of non-core assets is a common strategy for companies like Bioventus to improve focus and financial health, similar to actions taken by other medical device companies such as Medtronic and Stryker.
• The valuation of the transaction, with a $25 million upfront payment and up to $20 million in earn-outs, is within the typical range for similar deals in the HealthTech sector, although specific comparables would require more detailed financial information.
• Accelmed's investment strategy aligns with other private equity firms that focus on acquiring and growing commercial-stage companies, such as KKR and Carlyle Group, who have also made significant investments in the healthcare space.

Stakeholder Impact

• Shareholders will benefit from the increased liquidity and focus on core businesses.
• Employees in the divested business will transition to Accelmed Partners.
• Customers of the divested business will now be served by Accelmed Partners.

Next Steps

• Bioventus will focus on its core businesses.
• The company will monitor the buyer's performance to determine the earn-out payments.

Key Dates

Keywords

divestiture, acquisition, rehabilitation, bioventus, accelmed, healthtech, medical devices, earn-out, liquidity